American Heart Association

Inclisiran, a twice-yearly dosed therapy, significantly reduces LDL-C and improves adherence in ASCVD patients, with 84% achieving LDL-C <70 mg/dL in ORION-10 trial. Its unique RNA interference mechanism and long-term efficacy in ORION-8 support its real-world use, showing higher adherence than LCSK9 monoclonal antibodies.

Alnylam's Phase 1 data for nucresiran shows single doses ≥300mg achieve >90% TTR reduction by Day 15, sustained through Day 180, with peak reductions >96% by Day 29. At 300mg, TTR reduction remains >70% at Day 360, supporting potential biannual or annual dosing.

Intravenous exenatide did not significantly reduce death, stroke, or organ failure during cardiopulmonary bypass-assisted cardiac surgery, according to the GLORIOUS trial presented at the AHA Scientific Sessions 2024. The trial found no significant differences between exenatide and placebo in post-surgical outcomes over 5.9 years of follow-up.

Alnylam Pharmaceuticals' Phase 1 study of nucresiran shows rapid, sustained knockdown of serum TTR with mean reductions >90% at Day 15 and >70% at Day 360, with all doses well tolerated.

The BPROAD trial from China found that a systolic blood pressure target of less than 120 mm Hg reduced cardiovascular events by 21% in type 2 diabetes patients compared to a target under 140 mm Hg, with stroke being the primary driver. This aligns with findings from non-diabetic populations, suggesting similar responses to blood pressure treatments in diabetics.

Single doses of nucresiran ≥300mg rapidly reduced mean TTR levels >90% by Day 15, sustained at 6 months, with peak reductions >96% by Day 29. Potential for biannual or annual dosing, representing a new treatment paradigm for ATTR amyloidosis. Encouraging safety and tolerability observed. Phase 3 plans expected Q1 2025.

Tirzepatide, a GLP-1 and GIP receptor agonist, significantly reduces cardiovascular events in obese HFpEF patients, improving heart function and quality of life. Despite gastrointestinal side effects and access challenges, its potential as a 'practice-changing' treatment for obesity-induced HFpEF is promising.

The GLORIOUS trial found no significant benefits of exenatide infusion during heart surgeries involving bypass in preventing death, stroke, or organ injury. Researchers suggest further studies on other GLP-1 medications or longer/larger doses of exenatide.

Dr. Maya Balakrishnan explains distinguishing between heartburn and heart conditions, noting age-related risks and symptoms, and emphasizing the importance of consulting a doctor for persistent chest pain.